NEWS

News

January

13/01/2021

Philogen announces the completion of a second interim analysis of its phase III clinical program with NidlegyTM for the treatment of melanoma

  Press Release
x

By continuing to browse or by closing this window, you accept the use of cookies.

This website or its third party tools use cookies, which are necessary to its functioning and required to achieve the purposes illustrated in the cookie policy. By closing this banner or continuing to browse, you agree to the use of cookies.

I Accept Cookie Policy
X